Combining new drug with chemotherapy extends survival of platinum-resistant ovarian cancer patients in clinical trial

Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the last platinum dose, a condition referred to as platinum-resistant cancer. This form of cancer is a leading cause of gynecological cancer-related mortality.